BLS strikes agreement to bring novel depression therapy to Australian patients
BLS Pharmaceuticals (ASX: BLS) has entered into a non-binding Heads of Agreement with Trexapharm Pty Ltd for the proposed Australian commercialisation of TREXAVIVE®, a proprietary, patented neurotherapy for treatment-resistant depression.
The agreement is non-binding. It establishes the framework for the two parties to negotiate definitive commercial agreements rather than confirming a signed binding deal.
For investors, the significance lies in strategic direction. The collaboration would expand BLS’s mental health platform beyond medicinal cannabis and psychedelic medicines into a differentiated, non-sedating central nervous system (CNS) therapeutic.
Under the proposed structure, BLS would be appointed Trexapharm’s preferred Australian commercial partner.
Key details from the announcement include:
- Partner: Trexapharm Pty Ltd, a privately held, Australian CNS-focused drug development company
- Product: TREXAVIVE®, which combines low doses of flumazenil and naltrexone
- Structure: Non-binding Heads of Agreement
- Target indications: Treatment-resistant depression, Major Depressive Disorder, and trauma-related disorders including post-traumatic stress disorder (PTSD)
When big ASX news breaks, our subscribers know first
What the collaboration covers
The proposed collaboration would see BLS leverage its pharmaceutical manufacturing capabilities, commercial infrastructure and established healthcare relationships with psychiatrists, clinics and healthcare providers to support the therapy’s introduction into Australia.
Patient access would be supported through the Therapeutic Goods Administration’s Special Access Scheme (SAS) Category B and Authorised Prescriber pathways.
Trexapharm would retain responsibility for the clinical development of TREXAVIVE® and ownership of its intellectual property, which is protected by patents in Australia and the United States, together with additional international patent applications.
The parties also intend to explore Australian manufacturing of TREXAVIVE®, including subcutaneous infusion and nasal spray delivery systems.
Beyond the initial Australian scope, the two companies intend to explore several broader opportunities:
- International markets, including the United Kingdom
- Manufacturing and supply arrangements
- Veteran and defence mental health initiatives
- Broader commercial rights and partnerships
- Potential strategic investment opportunities
Each of these represents a potential future revenue or expansion vector. All remain exploratory and intended rather than committed, and no definitive terms have been agreed.
Understanding TREXAVIVE® and treatment-resistant depression
Treatment-resistant depression refers to cases where patients fail to respond to standard therapies. For these individuals, standard therapies do not deliver adequate relief, leaving limited options.
TREXAVIVE® has been designed as a non-sedating outpatient therapy administered within existing psychiatric workflows. According to the company, it does not require the sedation, dissociation or specialised hospital infrastructure often associated with some alternative next-generation mental health treatments.
Why does this matter to investors? The outpatient model aligns directly with BLS’s existing commercial infrastructure and healthcare relationships.
Early clinical experience reported by the parties includes:
- A small open-label study of 10 patients who had previously failed at least three therapies
- Symptom improvement observed from Day 4
- Encouraging preliminary safety, tolerability and efficacy signals
These findings remain preliminary and require confirmation in larger controlled clinical studies. They should not be interpreted as evidence of proven efficacy or regulatory approval.
Why this matters for BLS investors
TREXAVIVE® would broaden BLS’s mental health medicine offering into a differentiated CNS platform, complementing its existing medicinal cannabis and psychedelic medicine operations.
BLS’s psychedelic medicine operations have attracted commercial attention beyond Australia, with the company recently securing a referral agreement with Cayman Chemical that channels US and international customers seeking finished psilocybin and MDMA dosage forms directly to its GMP-licensed manufacturing platform.
The company’s platform credentials centre on GMP-licensed manufacturing through its wholly owned subsidiary, Breathe Life Sciences, with operations across Australia, Europe, the United Kingdom and Japan. Management has framed the agreement as a demonstration of the value of the commercial platform and healthcare relationships BLS has built.
Notably, no financial terms, deal value or milestone dates are disclosed in the announcement.
| Element | Detail | Investor Significance |
|---|---|---|
| Agreement type | Non-binding Heads of Agreement | Framework only; definitive agreements still to be negotiated |
| BLS role | Preferred Australian commercial partner | Positions BLS to leverage existing infrastructure and relationships |
| Therapeutic area | Non-sedating CNS therapy for treatment-resistant depression | Diversifies platform beyond cannabis and psychedelics |
| Clinical status | Preliminary data from a 10-patient open-label study | Encouraging but requires larger controlled trials |
| Financial terms | Not disclosed | Deal value and timelines remain unknown |
Managing Director Sam Watson framed the strategic rationale:
Sam Watson, Managing Director
“This proposed collaboration gives us the opportunity to support the introduction of differentiated, non-sedating treatment options to Australian psychiatrists and their patients, alongside our existing work in medicinal cannabis and psychedelic medicines.”
Trexapharm Executive Chairman Lee Rodne explained why BLS was selected:
Lee Rodne, Executive Chairman, Trexapharm
“We have been looking for the right commercial partner to help bring TREXAVIVE® to Australian patients, and BLS stood out because of its established pharmaceutical manufacturing capabilities, commercial infrastructure and growing leadership in regulated mental health therapies.”
What happens next
The Heads of Agreement provides a framework, not a completed transaction. The next step is for the parties to negotiate definitive commercial agreements.
Alongside the Australian commercialisation focus, the companies intend to progress discussions across manufacturing and supply, international expansion including the United Kingdom, veteran and defence mental health initiatives, and potential strategic investment.
No specific timelines have been disclosed. Investors should note the agreement remains non-binding at this stage, and its terms are subject to further negotiation before any definitive commitments are reached.
Don’t Miss the Next Healthcare Breakthrough on ASX
Big News Blast delivers FREE breaking ASX healthcare news straight to your inbox within minutes of release, complete with in-depth analysis already done for you. Join 20,000+ subscribers staying ahead of market-moving announcements. Click the “Free Alerts” button at StockWire X to get the next big healthcare story the moment it breaks.